Last reviewed · How we verify
NCT05974839: ORATORIO-Cort
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
trial testing Ocrelizumab in Primary Progressive Multiple Sclerosis in 732 participants. Completed in 28 February 2024.
28 February 2024
Quick facts
| Lead sponsor | State University of New York at Buffalo |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 732 |
| Start date | 1 October 2023 |
| Primary completion | 28 February 2024 |
| Estimated completion | 28 February 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Ocrelizumab (OCRELIZUMAB) — full drug profile →
Conditions studied
- Primary Progressive Multiple Sclerosis — all drugs for Primary Progressive Multiple Sclerosis →
Sponsor
State University of New York at Buffalo
Who can join
Adults 18 to 65, any sex, with Primary Progressive Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Potential of β-Synuclein-Specific Regulatory T Cell Therapy as a Treatment for Progressive Multiple Sclerosis.
Osmond GE, John NA, Ting YT, Ooi JD. · · 2025 · PMID 41373685 · DOI 10.3390/ijms262311534
Verify or expand the search:
- PubMed search for NCT05974839
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ocrelizumab
Trials testing the same drug.
- NCT06677710 — IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis · Phase 1 · suspended
- NCT07282574 — A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrel · Phase 2 · recruiting
- NCT06846281 — Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Scle · Phase 3 · recruiting
- NCT07483450 — A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Rel · Phase 4 · recruiting
- NCT06495593 — Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis · Phase 4 · enrolling by invitation
Other recruiting trials for Primary Progressive Multiple Sclerosis
Currently open trials in the same condition.
- NCT07483450 — A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Rel · Phase 4 · recruiting
- NCT05893225 — Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration · Phase 2 · active not recruiting
- NCT04688788 — Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis · Phase 3 · active not recruiting
- NCT03783416 — SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis · Phase 1 · recruiting
Other State University of New York at Buffalo trials
Trials by the same sponsor.
- NCT07072767 — Hybrid Dissemination Study of A Digital-Analog Intervention to Increase Live Donor Kidney Transplantation · NA · not yet recruiting
- NCT07140848 — CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes · NA · not yet recruiting
- NCT07433959 — Neuromodulation to Improve Grasping Function After SCI · NA · not yet recruiting
- NCT07403539 — Speech Learning and Speech Production in Parkinson's Disease · NA · recruiting
- NCT05367362 — Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute · Phase 2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05974839 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by State University of New York at Buffalo
- Last refreshed: 26 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05974839.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing